Palifermin
- Generic Name
- Palifermin
- Brand Names
- Kepivance
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 162394-19-6
- Unique Ingredient Identifier
- QMS40680K6
- Background
Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli.
Palifermin was granted FDA approval on 15 December 2004.
- Indication
For treatment of oral mucositis associated with chemotherapy and radiation therapy.
- Associated Conditions
- Oral Mucositis
- Associated Therapies
- -
Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2024-12-19
- Target Recruit Count
- 10
- Registration Number
- NCT06325709
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency
- First Posted Date
- 2017-10-19
- Last Posted Date
- 2019-12-04
- Target Recruit Count
- 13
- Registration Number
- NCT03315078
- Locations
- 🇺🇸
Laboratory of Host Defenses (LHD), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, United States
Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma
- First Posted Date
- 2016-11-11
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02961816
Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT02589145
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
- First Posted Date
- 2015-02-05
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 34
- Registration Number
- NCT02356159
- Locations
- 🇺🇸
National Marrow Donor Program, Minneapolis, Minnesota, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Palifermin for Patients Receiving Hematopoietic Stem Cell Transplantation
- First Posted Date
- 2014-12-10
- Last Posted Date
- 2014-12-10
- Lead Sponsor
- The Catholic University of Korea
- Target Recruit Count
- 88
- Registration Number
- NCT02313792
Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02114502
Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis
- Conditions
- Interventions
- First Posted Date
- 2014-01-15
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- Brett King
- Target Recruit Count
- 1
- Registration Number
- NCT02037347
- Locations
- 🇺🇸
Bridgeport Hospital, Bridgeport, Connecticut, United States
🇺🇸Yale-New Haven Hospital, New Haven, Connecticut, United States
CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2012-12-10
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 5
- Registration Number
- NCT01746173
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis
- First Posted Date
- 2012-10-24
- Last Posted Date
- 2019-04-30
- Target Recruit Count
- 40
- Registration Number
- NCT01712945
- Locations
- 🇬🇧
Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.